Zymeworks Inc., a global biotech company, has released a corporate presentation highlighting its advancements in targeted therapies for challenging diseases such as aggressive cancers and complex autoimmune disorders. The presentation details Zymeworks' focus on developing best-in-class multifunctional therapeutics, including the development of next-generation antibody-drug conjugates and multispecific antibody therapeutics. Key programs such as ZW191, ZW220, and ZW251 in solid tumor oncology are discussed, along with collaborations with partners like Jazz Pharmaceuticals and BeOne. The presentation also mentions Ziihera®, which has been approved for second-line HER2-positive biliary tract cancer. You can access the full presentation through the link below.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。